Fenwick Represents Sutro Biopharma in its $75 Million Underwritten Offering

Fenwick represented Sutro Biopharma (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), in its underwritten offering of 14,478,764 shares of its common stock at an offering price of $5.18 per share. The gross proceeds from this offering were approximately $75.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro.

BofA Securities acted as the sole book-running manager in the offering. More information can be obtained from Sutro Biopharma’s announcement.

The Fenwick transaction team included corporate partners Effie Toshav, Amanda Rose and Ryan Mitteness, associates Adam Conway and Meg Moloney and law clerk Abhi Bukkapatnam.